Home LiteratureArticle Details
PMID: 23644995 Published · ppublish English Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial.

JAMA ·Vol. 309 ·No. 20 ·2013-05-22 ·Pages 2111-20

Schmidt B, Whyte RK, Asztalos EV, Moddemann D, Poets C, Rabi Y, Solimano A, Roberts RS, Canadian Oxygen Trial COT Group

Abstract

The goal of oxygen therapy is to deliver sufficient oxygen to the tissues while minimizing oxygen toxicity and oxidative stress. It remains uncertain what values of arterial oxygen saturations achieve this balance in preterm infants. To compare the effects of targeting lower or higher arterial oxygen saturations on the rate of death or disability in extremely preterm infants. Randomized, double-blind trial in 25 hospitals in Canada, the United States, Argentina, Finland, Germany, and Israel in which 1201 infants with gestational ages of 23 weeks 0 days through 27 weeks 6 days were enrolled within 24 hours after birth between December 2006 and August 2010. Follow-up assessments began in October 2008 and ended in August 2012. Study participants were monitored until postmenstrual ages of 36 to 40 weeks with pulse oximeters that displayed saturations of either 3% above or below the true values. Caregivers adjusted the concentration of oxygen to achieve saturations between 88% and 92%, which produced 2 treatment groups with true target saturations of 85% to 89% (n = 602) or 91% to 95% (n = 599). Alarms were triggered when displayed saturations decreased to 86% or increased to 94%. The primary outcome was a composite of death, gross motor disability, cognitive or language delay, severe hearing loss, or bilateral blindness at a corrected age of 18 months. Secondary outcomes included retinopathy of prematurity and brain injury. Of the 578 infants with adequate data for the primary outcome who were assigned to the lower target range, 298 (51.6%) died or survived with disability compared with 283 of the 569 infants (49.7%) assigned to the higher target range (odds ratio adjusted for center, 1.08; 95% CI, 0.85 to 1.37; P = .52). The rates of death were 16.6% for those in the 85% to 89% group and 15.3% for those in the 91% to 95% group (adjusted odds ratio, 1.11; 95% CI, 0.80 to 1.54; P = .54). Targeting lower saturations reduced the postmenstrual age at last use of oxygen therapy (adjusted mean difference, -0.8 weeks; 95% CI, -1.5 to -0.1; P = .03) but did not alter any other outcomes. In extremely preterm infants, targeting oxygen saturations of 85% to 89% compared with 91% to 95% had no significant effect on the rate of death or disability at 18 months. These results may help determine the optimal target oxygen saturation. ISRCTN Identifier: 62491227; ClinicalTrials.gov Identifier: NCT00637169.

MeSH Terms
Adult Blindness/epidemiology,prevention & control Cognition Disorders/epidemiology,prevention & control Disabled Children Double-Blind Method Female Gestational Age Hearing Loss/epidemiology,prevention & control Humans Infant Infant, Newborn Infant, Premature Infant, Very Low Birth Weight Language Development Disorders/epidemiology,prevention & control Male Mortality/trends Odds Ratio Oxygen/blood Oxygen Inhalation Therapy/methods Retinopathy of Prematurity/epidemiology,prevention & control Treatment Outcome
Chemicals
Oxygen
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Schmidt Barbara
Division of Neonatology, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Philadelphia, PA, USA. [email protected]
Whyte Robin K
Asztalos Elizabeth V
Moddemann Diane
Poets Christian
Rabi Yacov
Solimano Alfonso
Roberts Robin S
Canadian Oxygen Trial (COT) Group
Investigators
123 investigators, click to expand
Shah Prakesh
Brown Leanne
Wenger Lisa
Frye Samantha
Imbesi Francesca
Kelly Edmond
D'Ilario Judy
Roy Madan
Schmidt Barbara
Dix Joanne
Adams Beth
Cairnie Janice
Gillie Patrice
Asztalos Elizabeth
Hyndman Marilyn
Lacy Maralyn
Hohn Denise
Kurk Laura Cooper
Abbasi Soraya
Mancini Toni
Sivieri Emidio
Finnegan Kathleen
Bairam Aida
Bélanger Sylvie
Deschenes Marianne
Fraser Annie
Harrold JoAnn
Frank Jane
Barden Julie
Whyte Robin
Vincer Michael
Stone Sharon
Rabi Yacov
Sauve Reg
Cyr Danielle
Christianson Heather
Anseeuw-Deeks Deborah
Creighton Dianne
Solimano Alfonso
Colby Lindsay
Butt Arsalan
Synnes Anne
Peterson Meredith
Schmidt Barbara
Chaudhary Aasma
Hurt Hallam
Foy Danielle
Ziolkowski Kristina
Gerdes Marsha
Bernbaum Judy
Peliowski Abraham
Kumar Manoj
Hendson Leonora
Athaide Melba
Tomlinson Jill
Poets Christian F
Bassler Dirk
Armbruster Jutta
Vain Nestor
Garcia Cecilia
DiGruccio Vanesa
Tamanaha Fernanda
Jacobi Noemí
Otamendi Sanatorio
Garcia Silvia
Vivas Norma
Osio Cristina
Sridhar Shanthy
Parekh Aruna
McGovern Rose
Arnon Shmuel
Meyer Michelle
Poller Rachel
Ali Nabeel
Khairy May
Paquet Isabelle
Perepolkin Larissa
Grier Patricia
Wali Sadia
Seshia Mary
Moddemann Diane
Minski John
Cook Valerie
Kwiatkowski Kim
Penner Karen A H
Williams Debbie
Givelichian Laurentiu
Sankaran Koravangattu
Thiel Cindy
Bader David
Sandler Bella
Chiu Aaron
Moddemann Diane
Everatt Dayle
Granke Naomi
Golan Agneta
Goldstein Esther
Dadoun Shlomith
Vikevainen Riitta
Kallankari Hanna
Kaukola Tuula
Hallman Mikko
Barrington Keith
Lavoie Julie
Schmidt Barbara
Asztalos Elizabeth V
Poets Christian F
Rabi Yacov
Roberts Robin S
Solimano Alfonso
Whyte Robin K
Moddemann Diane
Penner Karen A H
Fraser William
Davis Deborah
Wells George
D'Ilario Judy
Roberts Robin S
Costantini Lorrie
D'Ilario Judy
Yacura Wendy
Gent Bronwyn
Nelson Harvey
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
1538-3598
Published
2013-05-22
Pages
2111-20
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Grants
Canadian Institutes of Health Research · MCT-79217 · Canada
Databases
ClinicalTrials.gov
NCT00637169
ISRCTN
ISRCTN62491227
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]